Carlo C Cortes-Gonzalez

Dr. Carlo C Cortes-Gonzalez

Biomedical Cancer Research Unit, National Cancer Institute, Mexico City, Ciudad de México, Mexico
orcid
Cellular stress, molecular tracking & precision oncology

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2010 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
Jonatan Barrera-ChimalJonatan Barrera-Chimal
Jonatan Barrera-Chimal
RPRosalba Pérez‐Villalva
Rosalba Pérez‐Villalva
Carlo C Cortes-GonzalezCarlo C Cortes-Gonzalez
Carlo C Cortes-Gonzalez
MOMarcos Ojeda‐Cervantes
Marcos Ojeda‐Cervantes
GGGerardo Gamba
Gerardo Gamba
Norma A BobadillaNorma A Bobadilla
Norma A Bobadilla
This study was designed to assess whether heat shock protein Hsp72 is an early and sensitive biomarker of acute kidney injury (AKI) as well as to monitor a renoprotective strategy. Seventy‐two Wistar rats were divided into six groups: sham‐operated and rats subjected to 10, 20, 30, 45 and 60 min of bilateral ischemia (I) and 24 h of reperfusion (R). Different times of reperfusion (3, 6, 9, 12, 18, 24, 48, 72, 96 and 120 h) were also evaluated in 30 other rats subjected to 30 min of ischemia. Hsp72 messenger RNA (mRNA) and protein levels were determined in both kidney and urine. Hsp72‐specificity as a biomarker to assess the success of a renoprotective intervention was evaluated in rats treated with different doses of spironolactone before I/R. Renal Hsp72 mRNA and protein, as well as urinary Hsp72 levels, gradually increased relative to the extent of renal injury induced by different periods of ischemia quantified by histomorphometry as a benchmark of kidney damage. Urinary Hsp72 increased significantly after 3 h and continued rising until 18 h, followed by restoration after 120 h of reperfusion in accord with histopathological findings. Spironolactone renoprotection was associated with normalization of urinary Hsp72 levels. Accordingly, urinary Hsp72 was significantly increased in patients with clinical AKI before serum creatinine elevation. Our results show that urinary Hsp72 is a useful biomarker for early detection and stratification of AKI. In addition, urinary Hsp72 levels are sensitive enough to monitor therapeutic interventions and the degree of tubular recovery following an I/R insult.

3 April 2009 in Nephron Experimental Nephrology
Verified
Journal Article
Closed access
SMSara M. Molinas
Sara M. Molinas
Carlo C Cortes-GonzalezCarlo C Cortes-Gonzalez
Carlo C Cortes-Gonzalez
YGYvett González-Bobadilla
Yvett González-Bobadilla
LMLiliana A. Monasterolo
Liliana A. Monasterolo
CCCristino Cruz
Cristino Cruz
LTLaura Trumper
Laura Trumper
Background/Aims: Contributions to the understanding of acute renal failure (ARF) pathogenesis have not been translated into an effective clinical therapy. We studied the effects of pretreatment with the angiotensin II type 1 (AT1) receptor blocker, losartan, on renal function, tissue injury, inflammatory response and serum aldosterone levels in a model of ischemic ARF. Methods: Rats underwent unilateral renal ischemia followed by 24 h of reperfusion (IR), and were pretreated or not with 8 (IRL8) or 80 (IRL80) mg/kg/day of losartan for 3 days. Results: IR kidneys showed marked renal dysfunction, epithelial damage, capillary congestion, increased myeloperoxidase (MPO) activity and increased TNF-α, IL1-β and IL-6 mRNA levels. IRL80 kidneys showed protection against dysfunction and tissue injury, associated with normal MPO activity and cytokine mRNA levels. The lower dose was not able to achieve the same degree of functional renoprotection and could not prevent an increase of MPO or proinflammatory cytokine mRNA levels. The high losartan dose completely prevented an increase of serum aldosterone levels induced by IR. Conclusion: Renoprotection of the high losartan dose would be mainly mediated by its anti-inflammatory actions. Our results show a potential pathophysiological role of AT1 activation in promoting renal dysfunction, structural injury, inflammation and aldosterone elevation after IR injury.

9 August 2018 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
Jonatan Barrera-ChimalJonatan Barrera-Chimal
Jonatan Barrera-Chimal
LRLeslie Rocha
Leslie Rocha
Isabel Amador MartínezIsabel Amador Martínez
Isabel Amador Martínez
RPRosalba Pérez-Villalva
Rosalba Pérez-Villalva
RGRafael González
Rafael González
NBNorma A Bobadilla
Norma A Bobadilla
Acute kidney injury (AKI) is not as harmless as previously thought since it may lead to chronic kidney disease (CKD). Because most of the time ischemic AKI occurs unexpectedly, it is difficult to prevent its occurrence and there are no specific therapeutic approaches to prevent the AKI to CKD transition. We aimed to determine whether mineralocorticoid receptor blockade (MRB) in the first days after ischemia/reperfusion (IR) can prevent progression to CKD. Four groups of male Wistar rats were included: sham and three groups of bilateral renal ischemia for 45 min, one without treatment and the other two receiving spironolactone for 5 or 10 days, starting 24 h after IR. The rats were studied at 10 days or 5 months after ischemia induction. After 5 months of follow-up, the untreated group exhibited clear evidence of AKI to CKD progression, such as proteinuria, reduced renal blood flow, tubulointerstitial fibrosis, glomerulosclerosis and glomerular hypertrophy. All these alterations were prevented by both spironolactone treatments initiated 24 h after IR, the 10-day treatment being more effective. Within the early mechanisms of the MRB protective effect are the reduction of inflammation and increased endothelin-B-receptor expression and endothelial nitric oxide synthase activation in the first 10 days after IR. We propose that MRB, administered 24 h after the ischemic injury that leads to AKI, reduces inflammation and promotes efficient tissue repair that avoids the AKI to CKD transition. These data highlight a therapeutic window to preclude CKD development after AKI.

17 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
CACristian Arriaga-Canon
Cristian Arriaga-Canon
IRInti Alberto De La Rosa-Velázquez
Inti Alberto De La Rosa-Velázquez
RGRodrigo González-Barrios
Rodrigo González-Barrios
RMRogelio Montiel-Manríquez
Rogelio Montiel-Manríquez
DODiego Oliva-Rico
Diego Oliva-Rico
LHLuis A. Herrera
Luis A. Herrera
The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer

1 January 2010 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
Carlo C Cortes-GonzalezCarlo C Cortes-Gonzalez
Carlo C Cortes-Gonzalez
Jonatan Barrera-ChimalJonatan Barrera-Chimal
Jonatan Barrera-Chimal
MIMaría Ibarra-Sánchez
María Ibarra-Sánchez
MGMark Gilbert
Mark Gilbert
GGGerardo Gamba
Gerardo Gamba
NBNorma A. Bobadilla
Norma A. Bobadilla
Heat shock protein 90 subfamily is composed by two cytosolic isoforms known as Hsp90α and Hsp90β. Endothelial nitric oxide synthase (eNOS) is regulated by Hsp90, however the specific role of each Hsp90 isoform on NO production has not been established. This study was designed to evaluate the effect of Hsp90α and Hsp90β over-expression on eNOS/NO pathway. Rat Hsp90α and Hsp90β were cloned into pcDNA3.1(+) and transfected in human embryonic kidney cells (HEK-293). Hsp90α and Hsp90β transfection was corroborated by Western blot analysis and their effect on NO production (NO2/NO3), eNOS protein and its phosphorylation at Ser1177 and Thr495, as well as Akt/PKB Ser473 phosphorylation was determined. The interaction of Hsp90α and Hsp90β with eNOS and the dimer/monomer ratio of Hsp90, as well as O2- generation were also assessed. After transfection, Hsp90α and Hsp90β levels were significantly increased in HEK-293 cells. The Hsp90α over-expression induced a significant increase in NO2/NO3 levels, an effect that was associated with increased phosphorylation of eNOS Ser 1177 and Akt/PKB Ser473, as well as with a greater Hsp90α dimerization. Noteworthy, pcHsp90β transfection reduced significantly NO2/NO3 and increased O2- generation. These effects were associated with a reduction of eNOS dimeric conformation, increased eNOS Thr495 phosphorylation, reduced Akt/PKB phosphorylation, and by a greater amount of monomeric Hsp90β conformation. These data show for first time that Hsp90α and Hsp90β differentially modulate NO and O2- generation by eNOS through promoting changes in eNOS conformation and phosphorylation state.

1 January 2017 in Journal of Cancer
Verified
Journal Article
Open access
VGVerónica García-Castillo
Verónica García-Castillo
Eduardo López-UrrutiaEduardo López-Urrutia
Eduardo López-Urrutia
OVOctavio Villanueva-Sánchez
Octavio Villanueva-Sánchez
MÁMiguel Á. Ávila-Rodríguez
Miguel Á. Ávila-Rodríguez
AZAlejandro Zentella-Dehesa
Alejandro Zentella-Dehesa
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
Background: Chemotherapy is the backbone of systemic treatment for triple negative breast cancer (TNBC), which is one of the most relevant breast cancers molecular types due to the ability of tumor cells to develop drug resistance, highlighting the urgent need to design newer and safer drug combinations for treatment. In this context, to overcome tumor cell drug resistance, we employed a novel combinatorial treatment including Doxorubicin, Metformin, and Sodium Oxamate (DoxMetOx). Such pharmacological combination targets indispensable hallmarks of cancer-related to aerobic glycolysis and DNA synthesis.